Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 2824-2829

  Gu, Guo Long ^a   Xu, Xiao Lin ^b   Yang, Qing You ^c   Zeng, Ruo Long ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Cholesterol; Genetics; HDL; Lipid A

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CETP PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; Q WAVE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVASCULARIZATION; SURVIVAL RATE; BLOOD; CHINA; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ATORVASTATIN CALCIUM; CHINA; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEPTANOIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PYRROLES; SURVIVAL RATE;

EID: 84919941277     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892711     Document Type: Article

References (18)

1. Keene D, Price C, Shun-Shin MJ et al: Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ, 2014; 349: g4379
2. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statins treatment. Pharmacogenomics J, 2006; 6: 360–74
3. Ridker PM, MacFadyen JG, Glynn RJ et al: Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet, 2011; 4(3): 312–17
4. Williams P, Pendyala L, Superko R: Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease. BMC Med Genet, 2011; 12: 42
5. Lacchini R, Silva PS, Tanus-Santos JE: A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol, 2010; 106(5): 357–61
6. Maitland-van der Zee AH, Peters BJ et al: The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenet Genomics, 2009; 19(5): 338–44
7. Maitland-van der Zee AH, Lynch A, Boerwinkle E et al: Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics, 2008; 18(8): 651–56
8. Ahmad T, Chasman DI, Buring JE et al: Physical activity modifes the effect of LPL, LIPC*, and CETP polymorphisms on HDL-C levels and the risk of myocardial infarction in women of European ancestry. Circ Cardiovasc Genet, 2011; 4: 74–80
9. Shinkai H: Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag, 2012; 8: 323–31
10. Briand F: The use of dyslipidemic hamsters to evaluate drug induced alterations in reverse cholesterol transport. Curr Opin Investig Drugs, 2010; 11: 289–97
11. Redondo S, Martinez-Gonzalez J, Urraca C et al: Emerging therapeutic strategies to enhance HDL function. Lipids Health Dis, 2011; 10: 175
12. Charles MA, Kane JP: New molecular insights into CETP structure and function; a review. J Lipid Res, 2012; 53: 1451–58
13. Dachet C, Poirier O, Cambien F et al: New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/ Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol, 2000; 20: 507–15
14. Wang W, Zhou X, Liu F et al: Association of the Taq1B polymorphism and D442G mutation of cholesteryl ester transfer protein gene with coronary heart disease. Chin J Cardiol, 2004; 32: 981–85
15. Wu Y, Bai H, Liu R et al: Analysis of cholesterol ester transfer protein gene TaqIB and –629 C/A polymorphisms in patients with endogenous hypertri-glyceridemia in Chinese population, Chin J Med Genet, 2006; 23: 640–46
16. van Venrooij FV, Stolk RP, Banga JD et al: Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care, 2003; 26: 1216–23
17. Poduri A, Khullar M, Bahl A et al: Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol, 2010; 29: 629–37
18. Blankenberg S, Ruppreeht HJ, Bickel C et al: Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronaryartery disease. J Am Coll Cardiol, 2003; 41: 1983–89